Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse.
Predicting cancer patients' response to therapy is essential for curing disease and improving quality of life. Garraway and colleagues demonstrate that the frequency and number of neoantigens, non-synonymous mutations, and adaptive immune genes, but not the assessment of individual recurrent neoantigens or mutations, predicts patient responses to immunotherapy.
INSERM, UMRS1138, Laboratory of Integrative Cancer Immunology, Paris, 75006, France; Université Paris Descartes, Paris 75006, France; Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris 75006, France.
Sarah E
SE
Church
INSERM, UMRS1138, Laboratory of Integrative Cancer Immunology, Paris, 75006, France; Université Paris Descartes, Paris 75006, France; Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris 75006, France. Electronic address: jerome.galon@crc.jussieu.fr.
Jérôme
J
Galon
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000951:Antigens, Neoplasm / Q000235:genetics*; D054316:Biomarkers, Pharmacological; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D054316:Biomarkers, Pharmacological; D060908:CTLA-4 Antigen